Three large prospective cardiovascular outcome trials (ELIXA [on lixisenatide], LEADER [on liraglutide], and SUSTAIN-6 [on semaglutide]) have further demonstrated the low risk of HF associated with GLP-1 RAs [31]. This evidence concerns the gene GCG and hydrops fetalis.